DomeJS, MullenEA, DixDB, et al.Impact of the first generation of Children’s Oncology Group clinical trials on clinical practice for Wilms tumor. J Natl Compr Canc Netw2021;19:978–985.
DomeJS, MullenEA, DixDB, Impact of the first generation of Children’s Oncology Group clinical trials on clinical practice for Wilms tumor. J Natl Compr Canc Netw 2021;19:978–985.3441670510.6004/jnccn.2021.7070)| false
DixDB, SeibelNL, ChiYY, et al.Treatment of stage IV favorable histology Wilms tumor with lung metastases: a report from the Children’s Oncology Group AREN0533 study. J Clin Oncol2018;36:1564–1570.
DixDB, SeibelNL, ChiYY, Treatment of stage IV favorable histology Wilms tumor with lung metastases: a report from the Children’s Oncology Group AREN0533 study. J Clin Oncol 2018;36:1564–1570.10.1200/JCO.2017.77.193129659330)| false
GrundyPE, GreenDM, DirksAC, et al.Clinical significance of pulmonary nodules detected by CT and not CXR in patients treated for favorable histology Wilms tumor on national Wilms tumor studies-4 and -5: a report from the Children’s Oncology Group. Pediatr Blood Cancer2012;59:631–635.
GrundyPE, GreenDM, DirksAC, Clinical significance of pulmonary nodules detected by CT and not CXR in patients treated for favorable histology Wilms tumor on national Wilms tumor studies-4 and -5: a report from the Children’s Oncology Group. Pediatr Blood Cancer 2012;59:631–635.10.1002/pbc.24123)| false
DixDB, FernandezCV, ChiYY, et al.Augmentation of therapy for combined loss of heterozygosity of chromosomes 1p and 16q in favorable histology Wilms tumor: a Children’s Oncology Group AREN0532 and AREN0533 study report. J Clin Oncol2019;37:2769–2777.
DixDB, FernandezCV, ChiYY, Augmentation of therapy for combined loss of heterozygosity of chromosomes 1p and 16q in favorable histology Wilms tumor: a Children’s Oncology Group AREN0532 and AREN0533 study report. J Clin Oncol 2019;37:2769–2777.3144946810.1200/JCO.18.01972)| false
EhrlichPF, FerrerFA, RitcheyML, et al.Hepatic metastasis at diagnosis in patients with Wilms tumor is not an independent adverse prognostic factor for stage IV Wilms tumor: a report from the Children’s Oncology Group/National Wilms Tumor Study Group. Ann Surg2009;250:642–648.
EhrlichPF, FerrerFA, RitcheyML, Hepatic metastasis at diagnosis in patients with Wilms tumor is not an independent adverse prognostic factor for stage IV Wilms tumor: a report from the Children’s Oncology Group/National Wilms Tumor Study Group. Ann Surg 2009;250:642–648.1973024110.1097/SLA.0b013e3181b76f20)| false
FernandezCV, MullenEA, ChiYY, et al.Outcome and prognostic factors in stage III favorable-histology Wilms tumor: a report from the Children’s Oncology Group study AREN0532. J Clin Oncol2019;37:2710
FernandezCV, MullenEA, ChiYY, Outcome and prognostic factors in stage III favorable-histology Wilms tumor: a report from the Children’s Oncology Group study AREN0532. J Clin Oncol 2019;37:2710)| false
FernandezCV, MullenEA, ChiYY, et al.Outcome and prognostic factors in stage III favorable-histology Wilms tumor: a report from the Children’s Oncology Group study AREN0532. J Clin Oncol2018;36:254–261.
FernandezCV, MullenEA, ChiYY, Outcome and prognostic factors in stage III favorable-histology Wilms tumor: a report from the Children’s Oncology Group study AREN0532. J Clin Oncol 2018;36:254–261.10.1200/JCO.2017.73.7999)| false